The GXP environment is evolving as digital technologies are increasingly being applied to the development and manufacture of medicines.
This month sees the close of the consultation on the application of Analytical Quality by Design to pharmacopoeial standards. We sat down with Peter and Stephen, pharmacopoeial scientists for the British Pharmacopoeia, to discuss why this consultation may prove vital …
Sharing experience from recent events to help you safeguard the legitimate supply chain and avoid risks to public health
The definition of a falsified medicine and how to check that your systems comply
Implementation of the FMD safety features in the UK
An update on staff changes within the Inspectorate
This post provides some background information to the aims of the operational transformation programme and how the inspectorate is rising to the challenge.
Whilst we progress our latest recruitment campaign for GMDP Inspectors, Ian Holloway reflects on 30 years of working for the Medicines Regulator.
In the coming weeks, you will notice that it’s much quieter than usual on the MHRA Inspectorate blog. It’s because between midnight on Friday, 21 April and the general election on 8 June is the pre-election period.
From 10 April, we are removing .gsi from our email addresses. Technology has changed a lot since the introduction of the Government Secure Intranet (GSi) in 1996